Luspatercept 在成人地中海贫血中的应用
本文综述了 Luspatercept 在成人β-地中海贫血中的研发与临床证据。该药已于2019年和2020年分别在美欧获批。
要点
- BELIEVE试验中luspatercept组21.4%患者输血负担降低≥33%,安慰剂组仅4.5%。
- 任意12周区间输血负担降低≥33%者达70.5%(vs 29.5%)。
- 11%的luspatercept组患者实现输血独立。
核心结论
- Luspatercept可显著降低输血依赖型β-地中海贫血成人患者的输血负担,并已获美欧监管机构批准。
研究设计与样本
- 患者每21天皮下注射luspatercept或安慰剂并接受最佳支持治疗,疗程≥48周。
主要发现
- 任意滚动12周区间输血负担降低≥33%者luspatercept组70.5%、安慰剂组29.5%。
- 任意24周区间输血负担降低≥33%者luspatercept组41.1%、安慰剂组2.7%。
- luspatercept组11%患者实现输血独立。
- luspatercept组一过性不良事件较安慰剂组更常见,但可控。
关键数值与推荐
- 主要终点为输血负担降低≥33%。
临床怎么用
- Luspatercept适用于输血依赖型β-地中海贫血成人患者,可每21天皮下给药以降低输血负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Luspatercept is an activin receptor ligand trap that has been shown to enhance late-stage erythropoiesis in animal models of β-thalassemia. A multicenter, international, phase 2 dose-finding study was initiated in adult patients with β-thalassemia, either non-transfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT). Positive results of the phase 2 study paved the way to a randomized phase 3 clinical trial (BELIEVE) to assess the efficacy and safety of luspatercept. The BELIEVE trial is a randomized, double-blind, placebo-controlled phase 3 trial. Three hundred thirty-six patients aged ≥18 years with TDT (regularly transfused, 6-20 red blood cell units within 24 weeks before randomization) were included in the trial. Patients received luspatercept or placebo subcutaneously every 21 days for ≥48 weeks and best supportive care. Forty-eight of 224 patients (21.4%) in the luspatercept group achieved the primary end points (≥33% reduction in transfusion burden) compared with those in the placebo group (4.5%; P < .001). Moreover, more patients had a ≥33% reduction in transfusion burden during any rolling 12-week interval (70.5% vs 29.5%) or any 24-week interval (41.1% vs 2.7%) with luspatercept than with the placebo. Transfusion independence was achieved by 11% of patients in the luspatercept group. Transient adverse events were more frequent with luspatercept than with placebo, but were manageable. Luspatercept was approved by the US Food and Drug Administration in 2019 and by the European Medicines Agency in 2020. The luspatercept trial is registered on www.clinicaltrials.gov at #NCT01749540 and the BELIEVE trial at #NCT02604433.
引用
- Cappellini MD, Taher AT. The use of luspatercept for thalassemia in adults. Blood Adv. 2021. PMID: 33570654. doi:10.1182/bloodadvances.2020002725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。